# Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

> **NCT03687333** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 10 (actual)

## Conditions studied

- Glycogen Storage Disease Type II

## Interventions

- **DRUG:** ALGLUCOSIDASE ALFA (MYOZYME)

## Key facts

- **NCT ID:** NCT03687333
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03687333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03687333, "Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03687333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*